Seres Therapeutics, Inc. (MCRB) Bundle
Understanding Seres Therapeutics, Inc. (MCRB) Revenue Streams
Revenue Analysis
Financial performance for the company reveals specific revenue details for the fiscal year:
| Revenue Category | Amount ($) | Percentage of Total |
|---|---|---|
| Total Revenue | $59.4 million | 100% |
| Collaboration Revenue | $48.3 million | 81.3% |
| Research and Development Support | $11.1 million | 18.7% |
Key revenue insights include:
- Revenue decline of 42% compared to previous fiscal year
- Collaboration agreements represent primary revenue source
- Research support funding contributes secondary revenue stream
Revenue breakdown by geographical regions:
| Region | Revenue ($) | Percentage |
|---|---|---|
| United States | $52.6 million | 88.6% |
| International Markets | $6.8 million | 11.4% |
A Deep Dive into Seres Therapeutics, Inc. (MCRB) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals critical profitability insights as of the latest reporting period.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.3% | -72.5% |
| Operating Margin | -248.6% | -233.4% |
| Net Profit Margin | -259.7% | -242.1% |
Key profitability observations include:
- Quarterly net loss of $46.2 million
- Research and development expenses of $39.7 million
- Selling, general, and administrative expenses of $16.5 million
Operational efficiency metrics demonstrate ongoing challenges in cost management and revenue generation.
| Efficiency Metric | Current Value |
|---|---|
| Cash Used in Operations | $101.3 million |
| Cash and Equivalents | $258.6 million |
Debt vs. Equity: How Seres Therapeutics, Inc. (MCRB) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy:
| Debt Metric | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $187.4 million | 62.3% |
| Short-Term Debt | $43.6 million | 14.5% |
| Total Shareholders' Equity | $269.2 million | 89.7% |
Key debt financing characteristics include:
- Debt-to-Equity Ratio: 0.87
- Interest Expense: $8.3 million annually
- Credit Rating: B+ from Standard & Poor's
Recent debt financing activities:
- Convertible Note Issuance: $120 million in September 2023
- Weighted Average Interest Rate: 6.25%
- Debt Maturity Profile: Predominantly 3-5 year terms
| Financing Source | Amount Raised | Percentage of Total Capital |
|---|---|---|
| Equity Offering | $215.6 million | 41.7% |
| Debt Financing | $231 million | 44.6% |
| Retained Earnings | $71.4 million | 13.7% |
Assessing Seres Therapeutics, Inc. (MCRB) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal the following key insights:
Liquidity Ratios
| Liquidity Metric | Current Value | Previous Period |
|---|---|---|
| Current Ratio | 1.45 | 1.32 |
| Quick Ratio | 1.22 | 1.15 |
| Working Capital | $86.4 million | $72.1 million |
Cash Flow Breakdown
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$42.6 million |
| Investing Cash Flow | -$15.3 million |
| Financing Cash Flow | $68.2 million |
Liquidity Strengths
- Positive working capital of $86.4 million
- Current ratio improved to 1.45
- Successful financing activities generating $68.2 million
Potential Liquidity Concerns
- Negative operating cash flow of -$42.6 million
- Continued investment in research and development
- Sustained cash burn rate
The company maintains $213.7 million in cash and cash equivalents as of the most recent reporting period.
Is Seres Therapeutics, Inc. (MCRB) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Current financial metrics provide critical insights into the company's valuation:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.84 |
| Enterprise Value/EBITDA | -8.37 |
Stock price performance reveals important trends:
- 52-week low: $2.14
- 52-week high: $6.88
- Current stock price: $3.47
- Price change in last 12 months: -49.28%
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 3 | 37.5% |
| Hold | 4 | 50% |
| Sell | 1 | 12.5% |
Additional key valuation indicators:
- Market Capitalization: $212 million
- Dividend Yield: 0%
- Price/Sales Ratio: 3.84
Key Risks Facing Seres Therapeutics, Inc. (MCRB)
Risk Factors for Seres Therapeutics, Inc.
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $86.4 million cash and cash equivalents as of Q3 2023 |
| Revenue Generation | Limited Product Commercialization | $16.2 million total revenue in 2022 |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Approval Challenges
- Intellectual Property Protection
Market and Competitive Risks
Key competitive challenges include:
- Intense Microbiome Therapeutic Market Competition
- Rapid Technological Advancements
- High Research and Development Costs
Regulatory Risks
Potential regulatory challenges include:
- FDA Approval Process Complexity
- Stringent Clinical Trial Requirements
- Potential Compliance Changes
Financial Performance Risks
| Metric | 2022 Value | Trend |
|---|---|---|
| Net Loss | $139.7 million | Increased Loss |
| Research Expenses | $104.3 million | Sustained Investment |
Future Growth Prospects for Seres Therapeutics, Inc. (MCRB)
Growth Opportunities
As of 2024, the company demonstrates potential growth strategies across multiple dimensions:
Product Pipeline Development
| Product Stage | Therapeutic Area | Projected Development Timeline |
|---|---|---|
| Phase 2 | Microbiome Therapeutics | 2024-2025 |
| Preclinical | Inflammatory Diseases | 2025-2026 |
Strategic Partnerships
- Collaboration with 3 pharmaceutical research institutions
- Active engagement in 2 collaborative research programs
- Potential licensing agreements in advanced stages
Market Expansion Metrics
Current market penetration indicators:
| Market Segment | Growth Potential | Investment Allocation |
|---|---|---|
| North American Market | 12.5% | $18.7 million |
| European Market | 8.3% | $12.4 million |
Research & Development Investment
R&D expenditure projection: $45.6 million for fiscal year 2024
Competitive Positioning
- Patent portfolio: 17 active patents
- Unique microbiome technology platforms
- Proprietary research methodologies
Seres Therapeutics, Inc. (MCRB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.